Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Expression Pathology Inc patents


Recent patent applications related to Expression Pathology Inc. Expression Pathology Inc is listed as an Agent/Assignee. Note: Expression Pathology Inc may have other listings under different names/spellings. We're not affiliated with Expression Pathology Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "E" | Expression Pathology Inc-related inventors


Srm assay to indicate cancer therapy

The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the alk, ros, ron, ret, ts, and/or fgfr1 proteins that are particularly advantageous for quantifying the alk, ros, ron, ret, ts, and/or fgfr1 proteins directly in biological samples that have been fixed in formalin by the methods of selected reaction monitoring (srm) mass spectrometry, or as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. ... Expression Pathology Inc

Srm/mrm assays for cancer

Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by srm/mrm assay. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks. ... Expression Pathology Inc

Truncated her2 srm/mrm assay

This disclosure provides ten (10) specific peptides, and particular peptide characteristics, from the cell membrane-bound her2 protein and a diagnostic assay useful for determining the presence and amount of full length and truncated versions of the full-length her2 protein in cells derived from formalin fixed paraffin embedded tissue.. . ... Expression Pathology Inc

Methods of treating cancer by identification of patients sensitive to fgfr inhibitor therapy

Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring (srm) mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. ... Expression Pathology Inc

Methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy

Methods are provided for identifying whether a lung tumor will be responsive to treatment with the combination of the therapeutic agents cisplatin and pemetrexed. Specified ercc1, ts, p16, and frα fragment peptides are precisely detected and quantitated by srm-mass spectrometry directly in lung tumor cells collected from lung tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with the combination of cisplatin and pemetrexed therapeutic agents.. ... Expression Pathology Inc

Method for improved hepatocellular cancer diagnosis

Methods are provided for determining the diagnosis of whether a liver mass is a benign hepatocellular adenoma or a pre-malignant hepatocellular dysplastic nodule and/or a malignant hepatocellular carcinoma. Specific protein fragment peptides are precisely detected and quantitated by srm-mass spectrometry directly in liver mass cells collected from liver mass tissue that was obtained from a patient suffering from the liver mass and compared to reference levels in order to determine if the liver mass is a benign growth or a pre-cancer and/or cancer.. ... Expression Pathology Inc

Secreted protein acidic and rich in cysteine (sparc) protein srm/mrm assay

The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the secreted protein acidic and rich in cysteine (sparc) protein that are particularly advantageous for quantifying the sparc protein directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring (srm) mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. ... Expression Pathology Inc

Epidermal growth factor receptor (egfr) protein srm assay

The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the epidermal growth factor receptor (egfr) protein that are particularly advantageous for quantifying the egfr protein directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring (srm) mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. ... Expression Pathology Inc

Methods for treating her2-positive breast cancer

Methods of treating breast cancer are provided where a quantitative her2 assay is used to identify whether a breast tumor will be responsive to treatment with anti-her2 therapeutic agents such as lapatinib and trastuzumab, followed by selection of a suitable treatment regimen and administration of the regimen. A specific her2 fragment peptide is precisely quantitated by srm-mass spectrometry directly in breast tumor cells collected from breast tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the breast cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the her2 protein.. ... Expression Pathology Inc

Srm assays to chemotherapy targets

Methods are provided for quantifying the ent1, ercc1, folr1, rrm1, tubb3, topo1, and/or topo2a proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring (srm)/multiple reaction monitoring (mrm) mass spectrometry. The biological samples are treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks. ... Expression Pathology Inc

Srm/mrm assays

Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring (srm) mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed and can be tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. ... Expression Pathology Inc

Srm/mrm assay for the serine/threonine-protein kinase b-raf (braf)

The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the serine/threoninc-protein kinase b-raf (braf) that are particularly advantageous for quantifying the braf protein directly in bio-logical samples that have been fixed in formalin by the method of selected reaction monitoring (srm) mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.. ... Expression Pathology Inc

Srm/mrm assay for the gtpase kras protein (kras)

The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the gtpase kras protein (kras) that are particularly advantageous for quantifying the kras protein directly in biological samples that have been fixed in formalin by the mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells,. ... Expression Pathology Inc

Quantifying met protein for cancer treatment

Methods are provided for treating a gastric cancer patient. A specific met fragment peptide is precisely quantitated by srm-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. ... Expression Pathology Inc

02/23/17 / #20170052197

Srm/mrm assay for the androgen receptor (ar) protein

Methods are provided for quantifying the androgen receptor protein (ar) protein directly in biological samples that have been fixed in formalin, using selected reaction monitoring (srm)/multiple reaction monitoring (mrm) mass spectrometry. The biological samples are chemically preserved and fixed and can be, for example, tissues treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks. ... Expression Pathology Inc

02/02/17 / #20170030923

Quantifying fr-alpha and gart proteins for optimal cancer therapy

Improved methods are provided for treating cancer patients, particularly patients suffering from lung cancer. Methods are provided for identifying whether a lung tumor will be responsive to treatment with a therapeutic regimen that includes pemetrexed and optionally includes cisplatin. ... Expression Pathology Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Expression Pathology Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Pathology Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###